Ernexa Therapeutics (ERNAW) Receivables - Net (2010 - 2021)

Ernexa Therapeutics has reported Receivables - Net for 12 years, with the latest figure at $684000.0 in Q4 2021.

• For the quarter ending Q4 2021, Receivables - Net changed N/A year-over-year to $684000.0; the trailing twelve-month figure through Dec 2021 stood at $684000.0 (changed N/A YoY), and the FY2021 full-year result was $684000.0, changed N/A from the prior year.
• Receivables - Net for Q4 2021 stood at $684000.0, up from $24918.0 in the prior quarter.
• The five-year high for Receivables - Net was $1.8 million in Q1 2017, with the low at $24918.0 in Q1 2021.
• Historically, Receivables - Net has averaged $762182.4 across 5 years, with a median of $746500.0 in 2017.
• Annual changes were most pronounced in 2020 — Receivables - Net jumped 142.41% — and 2021, when it sank 93.49%.
• Ernexa Therapeutics' Receivables - Net stood at $714000.0 in 2017, then jumped by 60.08% to $1.1 million in 2018, then rose by 4.55% to $1.2 million in 2019, then slumped by 88.95% to $132000.0 in 2020, then surged by 418.18% to $684000.0 in 2021.
• The last three Receivables - Net figures came in at $684000.0 (Q4 2021), $24918.0 (Q1 2021), and $132000.0 (Q3 2020), per Business Quant data.